Semaglutide reduced the risk of kidney disease worsening, renal failure, and CV death by 24% compared with placebo. The approval was based on data from the randomized, double-blind, placebo-controlled ...

Semaglutide lowered the risk for kidney disease events by 24% in the FLOW trial. The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Credit: Novo Nordisk. The approval was based on data from the randomized, double-blind, placebo-controlled FLOW trial. Semaglutide reduced the risk of kidney disease worsening, renal failure ...

Semaglutide is now approved for T2D patients with CKD, reducing cardiovascular and kidney disease risks. The FLOW phase 3b trial showed significant reductions in adverse kidney and cardiovascular ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA ...

The trial achieved its primary endpoint with semaglutide 1 mg ... the risk of major kidney and cardiovascular outcomes,” said FLOW trial co-chair Richard E. Pratley, MD, medical director ...